Eton Pharmaceuticals Reports Record Q4 Revenue Growth

Eton Pharmaceuticals ( (ETON) ) has released its Q4 earnings. Here is a breakdown of the information Eton Pharmaceuticals presented to its investors.

Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, with a strong emphasis on pediatric endocrinology and metabolic conditions.

In its fourth quarter of 2024, Eton Pharmaceuticals reported record product revenue of $11.6 million, marking a 59% increase over the same period in 2023. This quarter was highlighted by the acquisition and relaunch of Increlex® and Galzin®, as well as the licensing of Amglidia® to enhance its pediatric endocrinology pipeline.

Key financial metrics include a gross profit of $6.5 million, up from $3.6 million in the previous year, driven by strong sales of ALKINDI SPRINKLE® and Carglumic Acid. The company also reported a net loss of $0.6 million, a significant improvement from the $2.3 million loss in the prior year. Strategic developments included the successful pivotal study results for ET-600 and preparation for the potential launch of ET-400.

Eton Pharmaceuticals is optimistic about its growth prospects in 2025, with the relaunch of Increlex® and Galzin® already exceeding expectations. The company is preparing for the potential approval and launch of ET-400 by May 28, 2025, and plans to submit an NDA for ET-600 in April 2025, aiming for approval in early 2026.